ARPA-H grants 2026: how to apply to the $945M federal health research agency
The Advanced Research Projects Agency for Health (ARPA-H) is the newest federal health research funder, established in 2022 and modeled on DARPA. Its FY2026 budget is $945 million, organized across five focus areas, with awards issued through Broad Agency Announcements (BAAs) rather than the NIH-style peer-reviewed grant cycle. ARPA-H is a different animal from NIH SBIR; the application format, evaluation criteria, and acceptable risk profile all differ. If you have a high-risk health innovation that NIH would call too speculative, ARPA-H may be your fit. To screen your concept against current open BAAs alongside SBIR opportunities, start with our grant finder.
📈 Time-bounded milestone-driven research: Yes. Program managers expect quarterly demos, not annual papers.
🔬 Investigator-curiosity basic science: No. Apply to NIH R01 or R21 instead. ARPA-H is mission-driven, not curiosity-driven.
What is ARPA-H?
ARPA-H was authorized by the Consolidated Appropriations Act of 2022 and operationally launched within HHS in March 2022. The agency is structurally independent from NIH: it has its own director, its own program managers, and its own contracting authority including Other Transactions Authority (OTA) that allows it to bypass the Federal Acquisition Regulation for many awards. This is the DARPA model applied to health.
The core operational unit is the program manager. Program managers serve fixed terms (typically 3 to 5 years), arrive with a specific program thesis, and run that program through to completion. They define the milestones, evaluate proposals, manage performer teams, and report up to the agency director. If your project aligns with an active program manager's thesis, you have a fundable opportunity; if not, no amount of proposal craft will work.
The five focus areas in 2026
ARPA-H's FY2026 portfolio is organized into five focus areas. Each focus area hosts multiple program managers and multiple open BAAs. Map your project to the focus area before identifying specific solicitations.
How ARPA-H applications work
ARPA-H typically uses a two-stage solicitation process under a BAA. Stage one is an abstract or white paper; only invited submissions proceed to stage two, the full proposal. This saves applicant effort on long-shots and lets program managers shape the pipeline.
| Stage | Deliverable | Length | Typical timeline |
|---|---|---|---|
| 1 --Abstract / white paper | Technical concept + team capability + cost summary | 8-15 pages | 2-4 weeks to write; 4-8 weeks ARPA-H review |
| 2 --Full proposal (invited) | Technical, management, cost, basis of estimate | 30-60 pages + appendices | 6-10 weeks to write; 8-12 weeks ARPA-H review |
| 3 --Award (varies) | Contract, grant, cooperative agreement, or Other Transaction | n/a | 4-8 weeks from selection to obligation |
The evaluation criteria are published in each BAA but consistently emphasize four dimensions: (1) technical merit against the program manager's thesis, (2) team capability with specific expertise mapped to milestones, (3) feasibility of the proposed milestones, and (4) cost-realism. Unlike NIH, ARPA-H weights team capability and execution risk heavily, and is willing to fund higher-risk technical paths if the team can demonstrate the execution discipline to manage that risk.
ARPA-H vs NIH vs BARDA
ARPA-H sits between NIH (basic and translational research) and BARDA (late-stage biodefense product development). The right agency depends on where your project sits on the discovery-to-product continuum.
ARPA-H vs NIH
NIH funds investigator-initiated research through R01, R21, and similar mechanisms. Peer reviewers evaluate the science; the PI sets the question. NIH is willing to fund decades-long programs of incremental progress.
ARPA-H funds program-driven research where ARPA-H sets the question and the milestones. Program managers select teams that can hit the milestones; teams that miss milestones are de-scoped or terminated. Time horizons are 3 to 5 years per program.
When to pick which: NIH for hypothesis-driven research where you control the agenda. ARPA-H if your project fits a published program manager's thesis and you can commit to milestone-driven execution.
ARPA-H vs BARDA
BARDA (Biomedical Advanced Research and Development Authority, within ASPR) funds late-stage development of medical countermeasures for biodefense, pandemic preparedness, and chemical/radiological/nuclear threats. BARDA awards are typically larger (tens to hundreds of millions) and require FDA-track product development.
ARPA-H funds earlier-stage research and is not restricted to biodefense scope. Awards are smaller and earlier on the development continuum.
When to pick which: BARDA if you have a clinical-stage product targeting a Public Health Emergency Medical Countermeasure list condition. ARPA-H if you are earlier-stage or outside biodefense scope.
ARPA-H vs NIH SBIR
NIH SBIR (covered in our SBIR Phase I 2026 guide) funds small business Phase I feasibility ($306K-$323K) and Phase II development ($2M+). Three standing deadlines per year, study-section peer review, investigator-initiated.
ARPA-H awards small businesses through BAAs that frequently exceed SBIR caps. Performer teams can include small businesses, universities, large companies, and nonprofits in consortium structures.
When to pick which: SBIR if you want investigator-initiated funding and you are small-business-only. ARPA-H if your project fits an active program thesis and you can lead a consortium.
Eligibility
ARPA-H BAAs accept proposals from a broader range of organizations than NIH SBIR. Each solicitation states its specific eligibility, but the typical floor is:
- U.S. organizations (for-profit, nonprofit, university, FFRDC). Some BAAs permit foreign collaborators or foreign-led teams; many do not.
- Consortium structures permitted and frequently expected. Performer teams that combine a small business technology lead, a university scientific lead, and a clinical site partner are common.
- No prior-revenue requirement. Early-stage companies regularly win abstracts; the team capability evaluation focuses on the team's ability to execute, not the company's commercial history.
- SAM.gov registration mandatory before submission. Begin registration the moment you decide to apply.
Funding trajectory and 2026 uncertainty
ARPA-H received approximately $1.5 billion in FY2025 appropriations. The FY2026 budget request provides $945 million, a meaningful reduction that has prompted advocacy coalitions to push for restoration to at least $1.7 billion[1]. Final FY2026 funding depends on whether Congress enacts a full-year appropriation bill (covering FY2026 through September 30, 2026) or operates the government under a continuing resolution that locks in prior-year levels.
Frequently asked questions
What is ARPA-H and how does it differ from NIH?
What is ARPA-H's FY2026 budget?
Who can apply for ARPA-H funding?
What are ARPA-H's focus areas in 2026?
How long does an ARPA-H application take to write?
Bottom line
ARPA-H is the newest, fastest-moving federal health research funder, with a $945M FY2026 budget across five focus areas and a DARPA-style program-manager-driven funding model. Apply if your project fits an active program manager's thesis, you can commit to milestone-driven execution, and you can assemble a consortium. Use NIH SBIR (covered in our SBIR Phase I 2026 guide) if you want investigator-initiated funding through standing deadlines, and BARDA for late-stage medical countermeasure development. The ARPA-H bet is on high-risk, time-bounded research that mainstream NIH would not fund; that selection bias is the feature, not a bug.